Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer

Status unconfirmed · Not applicable

Conditions studied: Dermatologic Complications, Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: Regenecare® wound gel may help relieve pain and itching in patients who develop an acne-like rash while undergoing treatment with cetuximab or another epidermal growth factor receptor inhibitor for cancer. PURPOSE: This clinical trial is studying how well Regenecare® wound gel works in treating rash in patients receiving cetuximab or another epidermal growth factor receptor inhibitor therapy for cancer.

Key facts

Study ID

NCT00498992

Run by

Ingalls Memorial Hospital

People needed

20

Starts

2006-07-01

Last updated by the study team

2013-09-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Ingalls Cancer Care Center at Ingalls Memorial Hospital — Harvey, Illinois, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.